Intrexon | XON - Net Income


Intrexon reported $-20.32M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Agenus USD 39.17M 49.8M Mar/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Amgen USD 2.38B 556M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
MannKind USD -16.62M 671K Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Thermo Fisher Scientific USD 1.74B 85M Jun/2026
Veracyte USD 25.49M 3.22M Jun/2026
Xencor USD -21.73M 107.19M Jun/2026